Literature DB >> 23817916

The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study.

Kunihiro Matsushita1, Emma K Williams, Morgana L Mongraw-Chaffin, Josef Coresh, Maria Ines Schmidt, Frederick L Brancati, Ron C Hoogeveen, Christie M Ballantyne, J Hunter Young.   

Abstract

We examined the association of plasma lactate at rest, a marker of oxidative capacity, with incident cardiovascular outcomes in 10,006 participants in the Atherosclerosis Risk in Communities (ARIC) Study visit 4 (1996-1998). We used Cox proportional-hazards models to estimate hazard ratios of incident coronary heart disease, stroke, heart failure, and all-cause mortality by quartiles of plasma lactate (Q1, ≤5.3 mg/dL; Q2, 5.4-6.6; Q3, 6.7-8.6; and Q4 ≥8.7). During a median follow-up time of 10.7 years, there were 1,105 coronary heart disease cases, 379 stroke cases, 820 heart failure cases, and 1,408 deaths. A significant graded relation between lactate level and cardiovascular events was observed in the demographically adjusted model (all P for trend < 0.001). After further adjustment for traditional and other potential confounders, the association remained significant for heart failure (Q4 vs. Q1: hazard ratio (HR) = 1.35, 95% confidence interval (CI): 1.07, 1.71) and all-cause mortality (HR = 1.27, 95% CI: 1.07, 1.51) (P for trend < 0.02 for these outcomes) but not for coronary heart disease (HR = 1.02, 95% CI: 0.84, 1.24) and stroke (HR = 1.26, 95% CI: 0.91, 1.75). The results for heart failure were robust across multiple subgroups, after further adjustment for N-terminal pro-B-type natriuretic peptide and after exclusion of participants with incident heart failure within 3 years. The independent associations of plasma lactate with heart failure and all-cause mortality suggest an important role for low resting oxidative capacity.

Entities:  

Keywords:  cardiovascular disease; epidemiology; heart failure; oxidative capacity; plasma lactate

Mesh:

Substances:

Year:  2013        PMID: 23817916      PMCID: PMC3727342          DOI: 10.1093/aje/kwt002

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  48 in total

1.  Cardiovascular risk factors emerge after artificial selection for low aerobic capacity.

Authors:  Ulrik Wisløff; Sonia M Najjar; Oyvind Ellingsen; Per Magnus Haram; Steven Swoap; Qusai Al-Share; Mats Fernström; Khadijeh Rezaei; Sang Jun Lee; Lauren Gerard Koch; Steven L Britton
Journal:  Science       Date:  2005-01-21       Impact factor: 47.728

2.  Fast predators or fast food, the fit still survive.

Authors:  Carlos Bernal-Mizrachi; Clay F Semenkovich
Journal:  Nat Med       Date:  2006-01       Impact factor: 53.440

Review 3.  Endurance exercise performance in Masters athletes: age-associated changes and underlying physiological mechanisms.

Authors:  Hirofumi Tanaka; Douglas R Seals
Journal:  J Physiol       Date:  2007-08-23       Impact factor: 5.182

4.  N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Authors:  Michael H Olsen; Tine W Hansen; Marina K Christensen; Finn Gustafsson; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Per R Hildebrandt
Journal:  Eur Heart J       Date:  2007-01-22       Impact factor: 29.983

5.  Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents.

Authors:  Katsutaro Morino; Kitt Falk Petersen; Sylvie Dufour; Douglas Befroy; Jared Frattini; Nadine Shatzkes; Susanne Neschen; Morris F White; Stefan Bilz; Saki Sono; Marc Pypaert; Gerald I Shulman
Journal:  J Clin Invest       Date:  2005-11-10       Impact factor: 14.808

6.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

7.  A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle.

Authors:  Lauren M Sparks; Hui Xie; Robert A Koza; Randall Mynatt; Matthew W Hulver; George A Bray; Steven R Smith
Journal:  Diabetes       Date:  2005-07       Impact factor: 9.461

8.  Abdominal fat distribution and functional limitations and disability in a biracial cohort: the Atherosclerosis Risk in Communities Study.

Authors:  D K Houston; J Stevens; J Cai
Journal:  Int J Obes (Lond)       Date:  2005-12       Impact factor: 5.095

9.  Relationship between blood pressure, metabolic variables and blood flow in obese subjects with or without non-insulin-dependent diabetes mellitus.

Authors:  P A Jansson; A Larsson; P N Lönnroth
Journal:  Eur J Clin Invest       Date:  1998-10       Impact factor: 4.686

10.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

View more
  13 in total

1.  GCKR and PPP1R3B identified as genome-wide significant loci for plasma lactate: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  A Tin; P Balakrishnan; T H Beaty; E Boerwinkle; R C Hoogeveen; J H Young; W H L Kao
Journal:  Diabet Med       Date:  2015-10-30       Impact factor: 4.359

2.  Targeted Metabolomic Profiling of Plasma and Survival in Heart Failure Patients.

Authors:  David E Lanfear; Joseph J Gibbs; Jia Li; Ruicong She; Christopher Petucci; Jeffrey A Culver; W H Wilson Tang; Yigal M Pinto; L Keoki Williams; Hani N Sabbah; Stephen J Gardell
Journal:  JACC Heart Fail       Date:  2017-11       Impact factor: 12.035

Review 3.  Advances in Glycolysis Metabolism of Atherosclerosis.

Authors:  Ruhan Xu; Wei Yuan; Zhongqun Wang
Journal:  J Cardiovasc Transl Res       Date:  2022-09-06       Impact factor: 3.216

4.  Elevated levels of urine isocitrate, hydroxymethylglutarate, and formiminoglutamate are associated with arterial stiffness in Korean adults.

Authors:  Ji-Hee Haam; Young-Sang Kim; Doo-Yeoun Cho; Hyejin Chun; Sang-Woon Choi; Yun Kyong Lee; Sang Wook Lim; Hyung Suk Koo; Moon Jong Kim
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

5.  Characterization of Lactate Sensors Based on Lactate Oxidase and Palladium Benzoporphyrin Immobilized in Hydrogels.

Authors:  Liam P Andrus; Rachel Unruh; Natalie A Wisniewski; Michael J McShane
Journal:  Biosensors (Basel)       Date:  2015-07-07

6.  Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease.

Authors:  Jorge L Gamboa; Frederic T Billings; Matthew T Bojanowski; Laura A Gilliam; Chang Yu; Baback Roshanravan; L Jackson Roberts; Jonathan Himmelfarb; T Alp Ikizler; Nancy J Brown
Journal:  Physiol Rep       Date:  2016-05

7.  Kidney Disease Measures and Left Ventricular Structure and Function: The Atherosclerosis Risk in Communities Study.

Authors:  Kunihiro Matsushita; Lucia Kwak; Yingying Sang; Shoshana H Ballew; Hicham Skali; Amil M Shah; Josef Coresh; Scott Solomon
Journal:  J Am Heart Assoc       Date:  2017-09-22       Impact factor: 5.501

8.  LACTATE CAN BE A MARKER OF METABOLIC SYNDROME IN SEVERE OBESITY?

Authors:  Roberto DE-Cleva; Lilian Cardia; Alexandre Vieira-Gadducci; Julia Maria Greve; Marco Aurelio Santo
Journal:  Arq Bras Cir Dig       Date:  2021-06-11

9.  Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial.

Authors:  Nerea Becerra-Tomás; Miguel Ruiz-Canela; Pablo Hernández-Alonso; Mònica Bulló; Jun Li; Marta Guasch-Ferré; Estefanía Toledo; Clary B Clish; Ramon Estruch; Emilio Ros; Montserrat Fitó; Chih-Hao Lee; Kerry Pierce; Fernando Arós; Lluís Serra-Majem; Liming Liang; Cristina Razquin; Enrique Gómez-Gracia; Miguel A Martínez-González; Frank B Hu; Dolores Corella; Jordi Salas-Salvadó
Journal:  Metabolites       Date:  2021-05-11

10.  Circulating peroxiredoxin 4 and type 2 diabetes risk: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.

Authors:  Ali Abbasi; Eva Corpeleijn; Ron T Gansevoort; Rijk O B Gans; Joachim Struck; Janin Schulte; Hans L Hillege; Pim van der Harst; Ronald P Stolk; Gerjan Navis; Stephan J L Bakker
Journal:  Diabetologia       Date:  2014-06-04       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.